Filtered By:
Condition: Hypertension
Cancer: Leukemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 43 results found since Jan 2013.

A Nationwide Analysis of Outcomes of Stroke in Hospitalized Patients with Essential Thrombocythemia: 2006 to 2014
Conclusions:Patients with ET who are hospitalized with stroke have significantly worse outcomes. This study demonstrated that a statistically significant difference exists among different age groups of patients with ET and stoke who died during hospitalization when stratification is made using age groups and Charlson Score. This study may serve as an initial point to include new risk factors for further risk stratification. Early identification of patients at higher risk may reduce the incidence and decrease the morbidity of stroke in patients with ET.DisclosuresKota: BMS: Honoraria; Novartis: Honoraria; Xcenda: Honoraria;...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ajebo, G., Badin, K., Forehand, W., Guddati, A. K., Kota, V. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster III Source Type: research

Scientists Discover a Bone-Deep Risk for Heart Disease
Few doctors, and even fewer patients, have heard of C.H.I.P. But it is emerging as a major cause of heart attacks and stroke, as deadly as high blood pressure or cholesterol.
Source: NYT Health - January 29, 2018 Category: Consumer Health News Authors: GINA KOLATA Tags: Heart Stem Cells Leukemia Genetics and Heredity Stroke Bone Marrow Blood Arteriosclerosis and Atherosclerosis McCarroll, Steven A (1970- ) Kathiresan, Sekar Walsh, Kenneth Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up
CONCLUSIONNilotinib is safe and highly effective in patients with AP-CML, and induces fast and durable responses. More than 50% of patients can achieve MR4.5. Clinical trial.gov: NCT00129740.DisclosuresCortes: novartis: Research Funding. O'Brien: Pfizer: Consultancy, Research Funding; Janssen: Consultancy; Aptose Biosciences Inc.: Consultancy; Kite Pharma: Research Funding; Regeneron: Research Funding; Vaniam Group LLC: Consultancy; Amgen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Celgene: Consultancy; Alexion: Consultancy; Abbvie: Consultancy; GlaxoSmithKline: Consultancy; Acerta: Research Funding; Gilead...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Cortes, J. E., Patel, K. P., O'Brien, S. M., Nogueras Gonzalez, G. M., Konopleva, M. Y., Verstovsek, S., Garcia-Manero, G., Ferrajoli, A., Kadia, T. M., Ravandi, F., Borthakur, G., Dellasala, S. E., Jabbour, E. J., Kantarjian, H. M. Tags: 632. Chronic Myeloid Leukemia: Therapy: Poster II Source Type: research

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia
CONCLUSION: CP-CML patients treated with different TKIs (ponatinib, bosutinib, imatinib, dasatinib, and nilotinib) did not have different incidence of cardiovascular events (MACE, AOEs, VTEs) in this small cohort of real-world patients with ≥6-month of follow-up. The results were consistent among patients with prior use of one and two TKI types.DisclosuresLevy: Takeda (Millennium Pharmaceuticals, Inc.): Consultancy. Xie: STATinMED Research: Employment. Wang: STATinMED Research: Employment. Neumann: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Srivastava: Takeda (Millennium Pharmaceuticals, Inc.): Employment. N...
Source: Blood - November 21, 2018 Category: Hematology Authors: Levy, M. Y., Xie, L., Wang, Y., Neumann, F., Srivastava, S., Naranjo, D., Zhang, Q., Dalal, M. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research

Environmental Pollution: An Under-recognized Threat to Children’s Health, Especially in Low- and Middle-Income Countries
Conclusions Patterns of disease are changing rapidly in LMICs. Pollution-related chronic diseases are becoming more common. This shift presents a particular problem for children, who are proportionately more heavily exposed than are adults to environmental pollutants and for whom these exposures are especially dangerous. Better quantification of environmental exposures and stepped-up efforts to understand how to prevent exposures that cause disease are needed in LMICs and around the globe. To confront the global problem of disease caused by pollution, improved programs of public health monitoring and environmental protecti...
Source: EHP Research - March 1, 2016 Category: Environmental Health Authors: Web Admin Tags: Brief Communication March 2016 Source Type: research

Increased Risk of Lymphoid Malignancy in Patients with Herpes Zoster: A Longitudinal Follow-up Study Using a National Cohort Study
Conclusion: Our study demonstrates that herpes zoster infection increases the risk of subsequent lymphoid malignancies irrespective of age and gender in the Korean population.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Lee, Y. K., Kim, M., Kim, H. J., Lim, H., Choi, H. G. Tags: 902. Health Services Research-Malignant Diseases: Quality Of Life Studies Source Type: research

Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research

Adiponectin as a routine clinical biomarker.
Abstract Adiponectin is a protein synthesized and secreted predominantly by adipocytes into the peripheral blood. However, circulating adiponectin level is inversely related with body weight, especially visceral fat accumulation. The mechanism of this paradoxical relation remains obscure. Low circulating adiponectin concentrations (hypoadiponectinemia; <4 μg/mL) are associated with a variety of diseases, including dysmetabolism (type 2 diabetes, insulin resistance, hypertension, dyslipidemia, metabolic syndrome, hyperuricemia), atherosclerosis (coronary artery disease, stroke, peripheral artery disease), slee...
Source: Clin Med Res - January 1, 2014 Category: Research Authors: Kishida K, Funahashi T, Shimomura I Tags: Best Pract Res Clin Endocrinol Metab Source Type: research

Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation Health Services and Outcomes
Conclusion Attention of clinicians to conventional cardiovascular risk factors and modifiable lifestyle characteristics offers hope of reducing serious cardiovascular morbidity after HCT.
Source: Journal of Clinical Oncology - January 17, 2014 Category: Cancer & Oncology Authors: Chow, Baker, Lee, Flowers, Cushing-Haugen, Inamoto, Khera, Leisenring, Syrjala, Martin Tags: Leukemia, Lymphoma, Myeloma, Outcomes Research Health Services and Outcomes Source Type: research

Abstract A12: Cancer communication in African American churches
Conclusion: Cancer was a frequent topic for disease-focused messages in African-American churches. In addition, three of the five most frequent disease topics matched the leading causes of death in the African-American community. The match was not as close in regards to leading causes of cancer death. Breast and prostate cancer information was frequently found; however, despite the high rates of mortality associated with lung cancer, colorectal cancer, and leukemia/lymphoma, information on these cancers was present much less frequently. No pancreatic cancer messages were found. Disease related information was seen that inc...
Source: Cancer Epidemiology Biomarkers and Prevention - November 13, 2014 Category: Cancer & Oncology Authors: Harmon, B. E., Chastain, E., Chock, M., Wirth, M., Hebert, J. R. Tags: Cancer Communications: Poster Presentations - Proffered Abstracts Source Type: research

Abstract 5267: Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL)
Conclusions. Despite the advanced age at CLL diagnosis, the frequent presence of comorbidities, and the indolent nature of the disease, CLL progression is the ultimate cause of death in 51% of newly diagnosed CLL patients, with an additional 26% dying of causes potentially related to CLL, such as infections and second cancers. The influence of comorbidities and other clinical factors at diagnosis (e.g. smoking, Charlson Comorbidity Index) on survival and ultimate cause of death are being abstracted, and will be presented at the meeting.Citation Format: Paolo Strati, Kari Chaffe, Sara Achenbach, Timothy Call, Neil Kay, Jame...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Strati, P., Chaffe, K., Achenbach, S., Call, T., Kay, N., Cerhan, J., Slager, S., Shanafelt, T. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Daily low-dose aspirin may help combat cancer
Conclusion The systematic review looked at 47 studies and attempted to combine the results, looking for evidence of a beneficial effect of low-dose aspirin on risk of death in people already diagnosed with cancer. The few RCTs identified – the best-quality evidence – did not provide conclusive evidence that aspirin improves survival rates. The rest of the studies were observational in nature, so cannot prove that aspirin reduces the risk of death from cancer. The only significant results were for a 24% reduction in risk of death from colon cancer, and a possible 11% reduced risk of death from prostate cancer. However,...
Source: NHS News Feed - April 22, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study Epidemiology
Conclusion Survivors of AYA cancer are at increased risk for developing CVD. Survival after CVD onset is compromised, and CVRFs are independent modifiers of CVD risk. These data form the basis for identifying high-risk individuals and proactive management of CVRFs.
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Chao, Xu, Bhatia, Cooper, Brar, Wong, Armenian Tags: Epidemiology Source Type: research